AUS
NZ
UK
CA
USA
IND
The giant ASX-listed healthcare stocks, Sonic Healthcare Ltd, is currently witnessing a decline in its share price, a movement that outpaces the broader ASX 200. The shares, which closed at $30.50, have fallen 4.6% to $29.09 at the time of writing. This drop comes in response to Sonic Healthcare's recent announcement of binding agreements to acquire Pathology Watch, a medical technology company based in Utah, USA.
In this strategic move, ASX SHL is set to pay US$130 million (approximately AU$200 million) for Pathology Watch, utilizing existing cash reserves and debt facilities for the transaction. The Utah-based company is recognized for developing and commercializing an integrated, end-to-end digital pathology platform specializing in skin pathology.
Despite Pathology Watch currently being in a pre-profit stage, Sonic Healthcare's management views this acquisition as a valuable opportunity. The company anticipates achieving attractive earnings per share and a return on invested capital accretion over the next few years.
The acquisition aligns with Sonic Healthcare's broader strategy, offering several opportunities for growth. These include accelerating Sonic's transition to digital pathology, gaining a competitive advantage in existing dermatopathology markets, and realizing significant synergies with its AI partner, Franklin.ai.
Colin Goldschmidt, CEO of Sonic Healthcare, expressed enthusiasm about the acquisition, stating that it represents a crucial step in the company's transition to digital pathology and pathology AI. He emphasized the multiple avenues for value creation and reiterated Sonic Healthcare's commitment to providing superior service offerings to referring physicians and their patients.
Despite the strategic significance of the acquisition, Sonic Healthcare's share price has faced a setback, pushing the stock into negative territory for the year 2023. Since January 3, the share price has seen a 1% decline.
The acquisition of Pathology Watch is expected to be finalized in December, subject to customary conditions. Sonic Healthcare anticipates that the founders, management team, and staff of Pathology Watch will continue their roles within the business.
Investors and industry observers are closely monitoring Sonic Healthcare's next steps as the company leverages this acquisition to enhance its digital pathology and AI strategy, aiming to maintain a competitive edge in the dynamic healthcare landscape.
